全文获取类型
收费全文 | 2547篇 |
免费 | 183篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 31篇 |
儿科学 | 49篇 |
妇产科学 | 54篇 |
基础医学 | 240篇 |
口腔科学 | 65篇 |
临床医学 | 237篇 |
内科学 | 527篇 |
皮肤病学 | 9篇 |
神经病学 | 178篇 |
特种医学 | 62篇 |
外科学 | 479篇 |
综合类 | 40篇 |
一般理论 | 3篇 |
预防医学 | 346篇 |
眼科学 | 34篇 |
药学 | 127篇 |
肿瘤学 | 251篇 |
出版年
2021年 | 30篇 |
2019年 | 28篇 |
2018年 | 29篇 |
2017年 | 27篇 |
2016年 | 29篇 |
2015年 | 22篇 |
2014年 | 38篇 |
2013年 | 101篇 |
2012年 | 106篇 |
2011年 | 132篇 |
2010年 | 66篇 |
2009年 | 48篇 |
2008年 | 131篇 |
2007年 | 105篇 |
2006年 | 110篇 |
2005年 | 125篇 |
2004年 | 137篇 |
2003年 | 111篇 |
2002年 | 110篇 |
2001年 | 59篇 |
2000年 | 46篇 |
1999年 | 47篇 |
1998年 | 18篇 |
1996年 | 24篇 |
1993年 | 18篇 |
1992年 | 41篇 |
1991年 | 52篇 |
1990年 | 36篇 |
1989年 | 40篇 |
1988年 | 29篇 |
1987年 | 38篇 |
1986年 | 40篇 |
1985年 | 28篇 |
1984年 | 28篇 |
1983年 | 25篇 |
1982年 | 25篇 |
1981年 | 23篇 |
1979年 | 26篇 |
1978年 | 22篇 |
1976年 | 23篇 |
1975年 | 18篇 |
1974年 | 34篇 |
1973年 | 23篇 |
1972年 | 39篇 |
1971年 | 31篇 |
1970年 | 26篇 |
1969年 | 39篇 |
1968年 | 32篇 |
1967年 | 24篇 |
1966年 | 28篇 |
排序方式: 共有2732条查询结果,搜索用时 15 毫秒
101.
102.
K‐John J. Cheung Allen Delaney Susana Ben‐Neriah Jacquie Schein Tang Lee Sohrab P. Shah Dorothy Cheung Nathalie A. Johnson Andrew J. Mungall Adele Telenius Betty Lai Merrill Boyle Joseph M. Connors Randy D. Gascoyne Marco A. Marra Douglas E. Horsman 《Genes, chromosomes & cancer》2010,49(8):669-681
A multiplatform approach, including conventional cytogenetic techniques, BAC array comparative genomic hybridization, and Affymetrix 500K SNP arrays, was applied to the study of the tumor genomes of 25 follicular lymphoma biopsy samples with paired normal DNA samples to characterize balanced translocations, copy number imbalances, and copy‐neutral loss of heterozygosity (cnLOH). In addition to the t(14;18), eight unique balanced translocations were found. Commonly reported FL‐associated copy number regions were revealed including losses of 1p32‐36, 6q, and 10q, and gains of 1q, 6p, 7, 12, 18, and X. The most frequent regions affected by copy‐neutral loss of heterozygosity were 1p36.33 (28%), 6p21.3 (20%), 12q21.2‐q24.33 (16%), and 16p13.3 (24%). We also identified by SNP analysis, 45 aberrant regions that each affected one gene, including CDKN2A, CDKN2B, FHIT, KIT, PEX14, and PTPRD, which were associated with canonical pathways involved in tumor development. This study illustrates the power of using complementary high‐resolution platforms on paired tumor/normal specimens and computational analysis to provide potential insights into the significance of single‐gene somatic aberrations in FL tumorigenesis. © 2010 Wiley‐Liss,Inc. 相似文献
103.
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. 总被引:1,自引:0,他引:1
Chris H Takimoto Martin A Graham Graham Lockwood Chee M Ng Andrew Goetz Dennis Greenslade Scot C Remick Sunil Sharma Sridhar Mani Ramesh K Ramanathan Timothy W Synold James H Doroshow Anne Hamilton Daniel L Mulkerin Percy Ivy Merrill J Egorin Jean L Grem 《Clinical cancer research》2007,13(16):4832-4839
PURPOSE: To characterize the pharmacokinetics and pharmacodynamics of oxaliplatin in cancer patients with impaired renal function. EXPERIMENTAL DESIGN: Thirty-four patients were stratified by 24-h urinary creatinine clearance (CrCL) into four renal dysfunction groups: group A (control, CrCL, >or=60 mL/min), B (mild, CrCL, 40-59 mL/min), C (moderate, CrCL, 20-39 mL/min), and D (severe, CrCL, <20 mL/min). Patients were treated with 60 to 130 mg/m2 oxaliplatin infused over 2 h every 3 weeks. Pharmacokinetic monitoring of platinum in plasma, plasma ultrafiltrates, and urine was done during cycles 1 and 2. RESULTS: Plasma ultrafiltrate platinum clearance strongly correlated with CrCL (r2 = 0.712). Platinum elimination from plasma was triphasic, and maximal platinum concentrations (Cmax) were consistent across all renal impairment groups. However, only the beta-half-life was significantly prolonged by renal impairment, with values of 14.0 +/- 4.3, 20.3 +/- 17.7, 29.2 +/- 29.6, and 68.1 h in groups A, B, C, and D, respectively (P = 0.002). At a dose level of 130 mg/m2, the area under the concentration time curve increased in with the degree of renal impairment, with values of 16.4 +/- 5.03, 39.7 +/- 11.5, and 44.6 +/- 14.6 mug.h/mL, in groups A, B, and C, respectively. However, there was no increase in pharmacodynamic drug-related toxicities. Estimated CrCL using the Cockcroft-Gault method approximated the measured 24-h urinary CrCL (mean prediction error, -5.0 mL/min). CONCLUSIONS: Oxaliplatin pharmacokinetics are altered in patients with renal impairment, but a corresponding increase in oxaliplatin-related toxicities is not observed. 相似文献
104.
Yaqoob Ali Yong Lin Mecide M Gharibo Murugesan K Gounder Mark N Stein Theodore F Lagattuta Merrill J Egorin Eric H Rubin Elizabeth A Poplin 《Clinical cancer research》2007,13(19):5876-5882
PURPOSE: Preclinical data shows improvements in response for the combination of imatinib mesylate (IM, Gleevec) and gemcitabine (GEM) therapy compared with GEM alone. Our goals were to determine the maximum tolerated dose of GEM and IM in combination, the pharmacokinetics of GEM in the absence and in the presence of IM, and IM pharmacokinetics in this combination. Patients and Methods: Patients with refractory malignancy, intact intestinal absorption, measurable/evaluable disease, adequate organ function, Eastern Cooperative Oncology Group PS 0-2, and signed informed consent were eligible. Initially, treatment consisted of 600 mg/m2 of GEM (10 mg/m2/min) on days 1, 8, and 15, and 300 mg of IM daily every 28 days. Due to excessive toxicity, the schedule was altered to IM on days 1 to 5 and 8 to 12, and GEM on days 3 and 10 every 21 days. Two final cohorts received IM on days 1 to 5, 8 to 12, and 15 to 19. RESULTS: Fifty-four patients were treated. IM and GEM given daily at 500 to 600 mg/m2 on days 1, 8, and 15 produced frequent dose-limiting toxicities. With the modified scheduling, GEM given at 1,500 mg/m2/150 min was deliverable, along with 400 mg of IM, without dose-limiting toxicities. Three partial (laryngeal, renal, and mesothelioma) and two minor (renal and pancreatic) responses were noted at GEM doses of 450 to 1,500 mg/m2. Stable disease >24 weeks was seen in 17 patients. CA19-9 in 7 of 10 patients with pancreatic cancer was reduced by approximately 90%. IM did not significantly alter GEM pharmacokinetics. CONCLUSION: The addition of intermittently dosed IM to GEM at low to full dose was associated with broad antitumor activity and little increase in toxicity. 相似文献
105.
Rusconi S Merrill DP La Seta Catamancio S Citterio P Bulgheroni E Croce F Chou TC Yang OO Herrmann SH Galli M Hirsch MS 《Antiviral therapy》2000,5(3):199-204
Compounds that can block the CXCR4 chemokine receptor are a promising new class of antiretroviral agents. In these experiments we studied the effect of a modified form of the native stromal cell-derived factor-1 (SDF-1), Met-SDF-1beta. The in vitro susceptibility of two different CXCR4-tropic HIV-1 strains was determined. Antiviral effect was assessed by the reduction of p24 antigen production in PHA-stimulated peripheral blood mononuclear cells with exposure to the modified SDF-1 molecule. The 50% inhibitory concentrations (IC50) were derived from six separate experiments. The IC50 against the two HIV-1 isolates was in 1.0-2.8 microg/ml range for Met-SDF-1beta. Met-SDF-1beta showed synergy to additivity with either zidovudine or nelfinavir at IC75 IC90 and IC95. Additivity was seen when Met-SDF-1beta was combined with efavirenz. No cellular toxicity was observed at the highest concentrations when these agents were used either singly or in combination. This compound is a promising new candidate in a receptor-based approach to HIV-1 infection in conjunction with currently available combination antiretroviral drug therapies. 相似文献
106.
Cancer prevalence estimates based on tumour registry data in the Surveillance, Epidemiology, and End Results (SEER) Program 总被引:4,自引:0,他引:4
Merrill RM Capocaccia R Feuer EJ Mariotto A 《International journal of epidemiology》2000,29(2):197-207
BACKGROUND: The Connecticut Tumor Registry (CTR) has collected cancer data for a sufficiently long period of time to capture essentially all prevalent cases of cancer, and to provide unbiased estimates of cancer prevalence. However, prevalence proportions estimated from Connecticut data may not be representative of the total US, particularly for racial/ethnic subgroups. The purpose of this study is to apply the modelling approach developed by Capocaccia and De Angelis to cancer data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute to obtain more representative US site-specific cancer prevalence proportion estimates for white and black patients. METHODS: Incidence and relative survival were modelled and used to obtain estimated completeness indices of SEER prevalence proportions for all cancer sites combined, stomach, cervix uteri, skin melanomas, non-Hodgkin's lymphomas, lung and bronchus, colon/rectum, female breast, and prostate. For validation purposes, modelled completeness indices were computed for Connecticut and compared with empirical completeness indices (the ratio of Connecticut based prevalence proportion estimates using 1973-1993 data to 1940-1993 data). The SEER-based modelled completeness indices were used to adjust SEER prevalence proportion estimates for white and black patients. RESULTS: Model validation showed that the adjusted SEER cancer prevalence proportions provided reasonably unbiased prevalence proportion estimates in general, although more complex modelling of the completeness indices is necessary for female cancers of the colon, melanoma, breast, cervix, and all cancers combined. The SEER-based cancer prevalence proportions are incomplete for most cancer sites, more so for women, whites, and at older ages. For all cancers combined, prevalence proportions tended to be higher for whites than blacks. For the site-specific cancers this was true for stomach, prostate, cervix uteri, and lung and bronchus (men only). For colon/rectal cancers the prevalence proportions were higher for blacks through ages 59 (men) and 64 (women), and then for the remaining ages they were higher for whites. Prevalence proportions were lowest for stomach cancer and highest for prostate and female breast cancers. Men experienced higher prevalence proportions than women for skin melanomas, non-Hodgkin's lymphomas, lung and bronchus, and colon/rectal cancers. CONCLUSION: The modelling approach applied to SEER data generally provided reasonable estimates of cancer prevalence. These estimates are useful because they are more representative of cancer prevalence than previously obtained and reported in the US. 相似文献
107.
D. I. Jodrell Lilian S. Murray Jeffrey Hawtof M. A. Graham Merrill J. Egorin 《Cancer chemotherapy and pharmacology》1996,37(4):356-362
The pharmacokinetics of a drug in individual patients can be estimated using plasma samples collected at a limited number
of time points. However, different methods for a limited-sampling strategy (LSS) design exist and the optimal method has not
yet been defined. Plasma concentration data were available from 27 of 74 courses in a phase I study (dose range, 5–55 mg m-2) of the novel anthrapyrazole DuP-941. Three approaches to LSS development were compared. Firstly, forward stepwise regression
(FSR) was used to derive equations to predict the DuP-941 area under the concentration-time curve (AUC) based on plasma concentrations
measured at specified times. LSSs were developed using 14 randomly chosen data sets and were validated using the remaining
13 data sets. Secondly, “all subsets” regression (ASR) was used to develop LSSs. A jack-knife technique was also used to allow
model development utilising 26 data sets and validation on the 27th data set. Thirdly, an LSS was developed using optimal
sampling theory (OST), and the LSS was used in conjuction with a Bayesian algorithm. Selected sampling times for four-point
LSSs were 10, 65, 185 and 485 min (FSR) and 10, 45, 200 and 480 min (OST). Ten candidate LSSs were developed using the ASR
approach. ASR- and OST/Bayesian-derived four-point LSSs gave more precise (P<0.05) estimates of AUC [mean absolute percentage of difference (MAD%) ± SD: ASR, 6.4±3.7%; OST/Bayesian, 6.8±4.6%] than
did FSR (MAD%=15.1±9.9%). The OST/Bayesian approach is recommended because it allows estimation of all model parameters and
is more flexible with regard to sample collection time and design variables.
Received: 23 January 1995/Accepted: 22 May 1995 相似文献
108.
J. L. Eiseman Zhi-Min Yuan Natalie D. Eddington Dorothy L. Sentz Patrick S. Callery Merrill J. Egorin 《Cancer chemotherapy and pharmacology》1996,38(1):13-20
The pharmacokinetics of 1, 19-bis(ethylamino)-5, 10, 15-triazanonadecane (BE-4-4-4-4) were determined in CD2F1 female mice after administration of i.v. bolus doses of 20 mg/kg (approximately the dose lethal to 10% of the study animals,
∼LD10) as well as 15, 10, and 5 mg/kg and after s.c., i.p., or p.o. doses of 20 mg/kg. BE-4-4-4-4 in plasma and urine was derivatized
with dansyl chloride and measured by gradient high-performance liquid chromatography (HPLC) with fluorescence detection. Data
were modeled by noncompartmental and compartmental methods. The declines observed in plasma BE-4-4-4-4 concentrations after
i.v. delivery of 20, 15, 10, and 5 mg/kg were modeled simultaneously using an interval of 2000 min between doses and were
best approximated by a two-compartment, open, linear model. The time courses of plasma BE-4-4-4-4 concentrations after i.p.
and s.c. delivery were fit best by a two-compartment, open, linear model with first-order absorption. Peak plasma concentrations
of BE-4-4-4-4 measured following an i.v. dose of 20 mg/kg ranged between 30 and 33 μg/ml, the terminal elimination half-life
was 94 min, and the volume of distribution (Vdss) was 850 ml/kg. The plasma pharmacokinetics of BE-4-4-4-4 were linear with dose. BE-4-4-4-4 (0.5 and 2.0 μM) in mouse plasma was approximately 67% protein-bound. Bioavailabilities after i.p., s.c., and p.o. delivery were 40%, 50%,
and approximately 3%, respectively. Urinary excretion of parent BE-4-4-4-4 in the first 24 h after dosing accounted for less
than 30% of the delivered dose. As BE-4-4-4-4 proceeds toward and undergoes clinical evaluation, the data and analytical method
presented herein should prove useful in formulating a dose-escalation strategy and, possibly, evaluating toxicities encountered.
Received: 25 November 1994/Accepted: 25 August 1995 相似文献
109.
110.
Two patients developed fat embolism syndrome after revision of loose total hip arthroplasties (THAs). During both procedures, the prosthesis became rigidly fixed 1 to 1.5 cm before the expected level of fixation. After uncomplicated operative courses, Patient A remained obtunded and febrile for 2.5 days, and Patient B died 1 day postoperatively. In Patient A, a presumptive diagnosis of fat embolism syndrome was based on the postoperative course and a radiograph of the lungs. In Patient B, the diagnosis was confirmed by evidence of cerebral edema on a computed tomography scan of the head. Fat embolism syndrome is unexpected after revision THA because the fatty tissue is removed from the femoral canal during primary THA. In these 2 cases, the rigid fixation and multiple attempts to impact and subsequently to remove the prosthesis may have caused fat embolism syndrome. 相似文献